Alterome Therapeutics Inc. has divulged substituted pyrido[4,3-d]pyrimidines acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.

Shenzhen Forward Pharmaceutical Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS G12C, G12D and G12V mutant inhibitors reported to be useful for the treatment of pancreatic cancer.

SK Biopharmaceuticals Co. Ltd. has divulged GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer.

Scientists at Healzen Therapeutics Co. Ltd. and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has identified GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Université de Montréal has disclosed GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and immunological disorders.

Merck Sharp & Dohme LLC has described compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized GTPase KRAS wild-type and/or its mutant inhibitors reported to be useful for the treatment of cancer.

Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory diseases and immunological disorders.

Abbisko Therapeutics Co. Ltd. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer.